Drug Profile
Cannabidiol/tetrahydrocannabinol - Axim Biotech
Alternative Names: CanChew®Rx; CanChew® RL; CBD/THC gum; MedChew 1401; MedChew 1502; MedChew 1503; MedChew 1504; MedChew GP; MedChew Rx; MedChew-RL; Tetrahydrocannabinol/cannabidiol - Axim BiotechLatest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator Axim Biotech
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antidementias; Antiemetics; Antiepileptic drugs; Antihyperglycaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Appetite stimulants; Cannabinoids; Chromans; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Non-opioid analgesics; Obesity therapies; Phytotherapies; Skin disorder therapies
- Mechanism of Action Cannabinoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Dementia; Pain; Parkinson's disease; Postherpetic neuralgia; Psychotic disorders; Restless legs syndrome
Most Recent Events
- 28 May 2023 No recent reports of development identified for preclinical development in Psychotic-disorders in USA (Buccal)
- 28 Apr 2021 No recent reports of development identified for preclinical development in Postherpetic-neuralgia in USA (Buccal, Gum)
- 28 Dec 2019 No recent reports of development identified for phase-I development in Dementia in USA (Buccal, Gum)